Cidara Therapeutics Q3 net loss widens

Cidara Therapeutics

06/11/2025 22:02

Overview

Cidara reports Q3 net loss of $83.2 mln, with no collaboration revenue

Company expands Phase 3 plan for CD388, enrolling over 50% in ANCHOR study

CD388 receives FDA Breakthrough Therapy designation, securing BARDA award

Result Drivers

PHASE 3 EXPANSION - Cidara's ANCHOR study for CD388 is over 50% enrolled, with expanded eligibility to include adults over 65, potentially doubling the target population

R&D expenses were $35.5 million for the three months ended September 30, 2025,  compared to $12.4 million  for the same periods in 2024

BARDA SUPPORT - BARDA award of up to $339.2 mln to support CD388 manufacturing and clinical development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$3.10
Q3 Net Income
-$83.23 mln
Q3 Operating Expenses
$88.63 mln
Q3 Operating Income
-$88.63 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cidara Therapeutics Inc is $170.00, about 42.6% above its November 5 closing price of $97.64

Press Release: ID:nGNX4pdNBS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)